Literature DB >> 28454341

The role of FADD in pancreatic cancer cell proliferation and drug resistance.

Rong Zhang1, Yingting Liu1, Kahina Hammache1, Liangqiang He1, Bo Zhu1, Wei Cheng1, Zi-Chun Hua1,2.   

Abstract

Pancreatic cancer has one of the poorest patient outcomes and is highly resistant to chemotherapy. Identifying the molecular mechanisms involved in drug resistance is critical in the development of novel strategies to treat pancreatic cancer. The results of the present study demonstrate that Fas-associated death domain protein (FADD), a classical adaptor protein mediating apoptotic stimuli-induced cell death, protects pancreatic cancer cells from drug-induced apoptosis. In contrast to its classical apoptotic roles, it was observed that FADD is required for pancreatic cancer cell proliferation and that it is overexpressed to varying degrees in various types of pancreatic cancer cell. This leads to differing levels of drug resistance in pancreatic cancer cells, where drug resistance is positively correlated with FADD expression. Notably, the results of the present study demonstrate that FADD protects pancreatic cancer cells from drug-induced apoptosis, while RNA interference of FADD sensitizes drug-resistant cells to Adriamycin®-mediated apoptosis. The results of the present study reveal unexpected roles for FADD in pancreatic cancer cell proliferation and drug resistance.

Entities:  

Keywords:  Adriamycin®; Fas-associated death domain protein; apoptosis; cell cycle; pancreatic cancer

Year:  2017        PMID: 28454341      PMCID: PMC5403491          DOI: 10.3892/ol.2017.5636

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  27 in total

1.  FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis.

Authors:  A M Chinnaiyan; K O'Rourke; M Tewari; V M Dixit
Journal:  Cell       Date:  1995-05-19       Impact factor: 41.582

Review 2.  Cell cycle regulation and apoptosis.

Authors:  K L King; J A Cidlowski
Journal:  Annu Rev Physiol       Date:  1998       Impact factor: 19.318

3.  FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation.

Authors:  Patrick-Simon Welz; Andy Wullaert; Katerina Vlantis; Vangelis Kondylis; Vanesa Fernández-Majada; Maria Ermolaeva; Petra Kirsch; Anja Sterner-Kock; Geert van Loo; Manolis Pasparakis
Journal:  Nature       Date:  2011-07-31       Impact factor: 49.962

4.  Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome.

Authors:  Léa Tourneur; Stéphanie Delluc; Vincent Lévy; Françoise Valensi; Isabelle Radford-Weiss; Ollivier Legrand; Jacques Vargaftig; Charlotte Boix; Elizabeth A Macintyre; Bruno Varet; Gilles Chiocchia; Agnès Buzyn
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

5.  FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis.

Authors:  W C Yeh; J L de la Pompa; M E McCurrach; H B Shu; A J Elia; A Shahinian; M Ng; A Wakeham; W Khoo; K Mitchell; W S El-Deiry; S W Lowe; D V Goeddel; T W Mak
Journal:  Science       Date:  1998-03-20       Impact factor: 47.728

6.  Phosphorylation of FADD at serine 194 by CKIalpha regulates its nonapoptotic activities.

Authors:  Elizabeth C Alappat; Christine Feig; Benjamin Boyerinas; Jörg Volkland; Martin Samuels; Andrea E Murmann; Andrew Thorburn; Vincent J Kidd; Clive A Slaughter; Stephanie L Osborn; Astar Winoto; Wei-Jen Tang; Marcus E Peter
Journal:  Mol Cell       Date:  2005-08-05       Impact factor: 17.970

7.  A mouse Fas-associated protein with homology to the human Mort1/FADD protein is essential for Fas-induced apoptosis.

Authors:  J Zhang; A Winoto
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

8.  Self-renewal and differentiation of muscle satellite cells are regulated by the Fas-associated death domain.

Authors:  Wei Cheng; Lu Wang; Bingya Yang; Rong Zhang; Chun Yao; Liangqiang He; Zexu Liu; Pan Du; Kahina Hammache; Juan Wen; Huang Li; Qiang Xu; Zichun Hua
Journal:  J Biol Chem       Date:  2013-12-27       Impact factor: 5.157

9.  Pancreatic cancer: chemotherapy and radiotherapy.

Authors:  Ake Andrén-Sandberg
Journal:  N Am J Med Sci       Date:  2011-01

10.  Functional complementation between FADD and RIP1 in embryos and lymphocytes.

Authors:  Haibing Zhang; Xiaohui Zhou; Thomas McQuade; Jinghe Li; Francis Ka-Ming Chan; Jianke Zhang
Journal:  Nature       Date:  2011-03-02       Impact factor: 49.962

View more
  7 in total

1.  Bioinformatic Prediction of Possible Targets and Mechanisms of Action of the Green Tea Compound Epigallocatechin-3-Gallate Against Breast Cancer.

Authors:  Xinqiang Song; Mu Zhang; Lei Chen; Qingsong Lin
Journal:  Front Mol Biosci       Date:  2017-06-30

2.  Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer.

Authors:  Wenli Qiu; Rong Chen; Xiao Chen; Huifeng Zhang; Lina Song; Wenjing Cui; Jingjing Zhang; Dandan Ye; Yifen Zhang; Zhongqiu Wang
Journal:  Int J Nanomedicine       Date:  2018-10-24

3.  Cancer-related proteins in serum are altered in workers occupationally exposed to polycyclic aromatic hydrocarbons: a cross-sectional study.

Authors:  Ayman Alhamdow; Håkan Tinnerberg; Christian Lindh; Maria Albin; Karin Broberg
Journal:  Carcinogenesis       Date:  2019-07-06       Impact factor: 4.944

4.  Peritumoural adipose tissue pro-inflammatory cytokines are associated with tumoural growth factors in cancer cachexia patients.

Authors:  Nelson Inácio Pinto Neto; Ariene Soares de Pinho Murari; Lila Missae Oyama; José Pinhata Otoch; Paulo Sérgio Martins Alcântara; Flavio Tokeshi; Raquel Galvão Figuerêdo; Michele Joana Alves; Joanna Darck Carola Correia Lima; Emídio Marques de Matos-Neto; Marilia Seelaender; Claudia Maria Oller do Nascimento
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-10-03       Impact factor: 12.910

5.  Knock down of Fas-Associated Protein with Death Domain (FADD) Sensitizes Osteosarcoma to TNFα-induced Cell Death.

Authors:  Mario G Hollomon; LaNisha Patterson; Janice Santiago-O'Farrill; Eugenie S Kleinerman; Nancy Gordon
Journal:  J Cancer       Date:  2020-01-14       Impact factor: 4.207

Review 6.  FADD in Cancer: Mechanisms of Altered Expression and Function, and Clinical Implications.

Authors:  José L Marín-Rubio; Laura Vela-Martín; José Fernández-Piqueras; María Villa-Morales
Journal:  Cancers (Basel)       Date:  2019-09-29       Impact factor: 6.639

7.  Association between ANGPTL-4 and the proinflammatory process in cancer cachexia patients.

Authors:  Nelson Inácio Pinto Neto; Valter Tadeu Boldarine; Ana Claudia Losinskas Hachul; Lila Missae Oyama; Joanna Darck Carola Correia Lima; Estefania Simoes Fernandez; José Pinhata Otoch; Paulo Sérgio Martins de Alcântara; Flavio Tokeshi; Marilia Cerqueira Leite Seelaender; Claudia Maria da Penha Oller do Nascimento
Journal:  Oncotarget       Date:  2019-11-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.